KNIGHT CAPITOL CONSULTANTS for REGENXBIO
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):to any successor to the Guthrie-Schrader MVP Act (formerly HR 7389) authorizing Medicaid value-based payments; -Changes to the Orphan Drug Act; -legislation affecting reimbursement of pharmaceuticals, including potential amendments to the Inflation Reduction Act; -
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch |
Medicare/Medicaid MMM
Potential amendments to the Social Security Act to allow value-based pricing under Medicaid (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Pharmacy PHA
Development of legislation that would affect the research, regulation or pricing of biopharmaceuticals (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Taxation/Internal Revenue Code TAX
Monitor discussion of proposals to affect the R&D Tax Credit (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.